Sillyspuh Posted - 1 week ago

$AURA What happened??

TickerDD_com Posted - 1 week ago

$AURA How much is AUR Shorted? What is Short Interest for AUR? https://youtu.be/uIFSu3rBEaY

insiderbuyingselling Posted - 10/29/24

$AURA new insider selling: 553 shares. http://insiderbuyingselling.com/?t=AURA

bigkahunatrader Posted - 10/23/24

$AURA AURA Biosciences, Inc. CAT-3 TM-5 cycle set...watching this pullback https://youtu.be/N5Nr97Tpiwo

SPACEDAD Posted - 10/22/24

$AURA I'm going to go long on this. Not a massive position but I have a hunch this is a sleeper.

insiderbuyingselling Posted - 1 month ago

$AURA new insider selling: 25131 shares. http://insiderbuyingselling.com/?t=AURA

Thestocktraderhubzee Posted - 1 month ago

WATCHLIST OCT 21 2024.. $AURA Scotiabank Maintains Sector Outperform on Aura Biosciences, Raises Price Target to $23 $KEY Barclays Maintains Equal-Weight on KeyCorp, Raises Price Target to $19 $STEM Barclays Maintains Equal-Weight on Stem, Lowers Price Target to $1 $GMRE Berenberg Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $11.75 $DCTH Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target

PenkeTrading Posted - 1 month ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Aura Biosciences Inc. Is that bullish or bearish? $AURA #RsiOverbought #NASDAQ

insiderbuyingselling Posted - 1 month ago

$AURA new insider selling: 24992 shares. http://insiderbuyingselling.com/?t=AURA

SPACEDAD Posted - 1 month ago

$AURA I'll swing a small pile of these over the weekend.

Teamnosleep25 Posted - 1 month ago

$AURA yeah but with need people (volume )

topstockalerts Posted - 1 month ago

$AURA too strong to ignore..

Benzinga Posted - 1 month ago

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease $AURA https://www.benzinga.com/general/biotech/24/10/41401926/aura-biosciences-bladder-cancer-candidate-demonstrates-tumor-shrinkage-in-patients-with-high-grad

Harlaxton Posted - 1 month ago

$AURA been holding this one since December 2023. Looks like it could be a big winner!

OpenOutcrier Posted - 1 month ago

$AURA (+6.9% pre) Aura Biosciences (AURA): Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) - SI https://ooc.bz/l/45113

Quantumup Posted - 1 month ago

BTIG⬆️PT $AURA $24 +⬆️bel-sar PoS in NMIBC to 75%. NMIBC is w/out a function-sparing Tx option that=potent abscopal effect/P1 data show bel-sar can likely thrive in this non-ocular opp—70%-80% of pts=recurrence w/ SoC—views as🐘unmet need opp4differentiation: HCW⬆️PT $AURA $22 +⬆️NMIBC PoS to 25%:

themacromindset Posted - 1 month ago

$AURA Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

tradingtwenty Posted - 1 month ago

$AURA has trended 16 times in the past 24 hours (based on 5 minute intervals). Latest press release on Oct 17, 2024 04:05 PM: Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with... Link: https://tradingtwenty.com/news/661023/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-of-bel-sar-in-patients-with-non-muscle-invasive-bladder-cancer-nmibc-in-ongoing-phase-1-trial

DonCorleone77 Posted - 1 month ago

$NFLX $ISRG $AURA $WAL $CCK Please feel free to follow me for pre-market and after-hours movers every day. AFTER-HOURS MOVERS: Currently Higher After Earnings: -- Intuitive Surgical (ISRG) up 6.0% -- Netflix (NFLX) up 4.9%; Streaming ecosystem names higher: Roku (ROKU) up 1.0%, Disney (DIS) up 0.3% -- Crown Holdings (CCK) up 3.1% -- OceanFirst Financial (OCFC) up 2.0% -- Bank OZK (OZK) up 0.5% Currently Also Higher: -- Aura Biosciences (AURA) up 7.4% after announcing early data from bel-sar trial Currently Lower After Earnings: -- Western Alliance (WAL) down 4.9% -- F.N.B. Corporation (FNB) down 1.1% -- Marten Transport (MRTN) down 1.5% Currently Also Lower: -- MGP Ingredients (MGPI) down 18.1% after below-consensus Q3 pre-announcement

Freddie___Mac Posted - 1 month ago

$AURA should be up a lot more. results are very strong

Teamnosleep25 Posted - 1 month ago

$AURA to the moon 🎉🎉$50

DonCorleone77 Posted - 1 month ago

$AURA Aura Biosciences announces early data from bel-sar trial Aura Biosciences announced early data from an ongoing Phase 1 clinical trial of bel-sar in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone and bel-sar with light activation. The secondary endpoints are to evaluate biological activity and immune mediated changes in the tumor microenvironment, or TME. Ten of 13 study participants had low grade disease, approximating the 70% incidence of this patient population among all NMIBC patients. The other three study participants had high grade disease. In patients receiving bel-sar with light activation, 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation. Two out of 3 patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy. Aura will host a Virtual Urologic Oncology Investor Event at 4:30 pm ET. The ongoing Phase 1 trial is a two-part, open-label clinical trial, designed to assess the safety and feasibility of bel-sar as a monotherapy. The study treatment is administered 7 to 12 days before the scheduled transurethral resection of bladder tumor, or TURBT, the standard of care procedure. The participants are followed for safety monitoring over a 56-day period. The trial is also evaluating bel-sar's biological activity with histopathological evaluation of tissue samples collected at the time of TURBT with evaluation of focal necrosis and immune changes in the tumor microenvironment. Part 1 of the trial is complete, with patients receiving a single bel-sar dose without light activation. Part 2 of the trial is ongoing. Eight patients with a confirmed tumor at time of treatment have received either 100ug or 200ug of bel-sar as a single dose. Of these eight patients, five had low grade disease and three had high grade disease. Seven of these eight patients had a history of recurrent bladder cancer and had undergone multiple TURBTs and adjuvant treatments such as Bacillus Calmette-Guerin, mitomycin, gemcitabine, cetrelimab and tamoxifen prior to trial enrollment. In the Phase 1 trial expansion, Aura plans to test additional doses and treatment regimens. In the safety analysis as of the September 9 data cut-off date, bel-sar was well-tolerated, with less than 10% of patients reporting Grade 1 and no Grade 2 or higher drug-related adverse events reported. No serious adverse events have been reported. No significant differences between the light-activated and non-light activated cohorts have been observed. The data in these 8 patients receiving bel-sar with light activation showed clinical activity detectable as soon as 7 days after a single low dose of bel-sar with light activation. This was demonstrated by histopathological evidence of clinical complete response, necrosis, immune activation or visual tumor shrinkage observed on cystoscopy. For this analysis, "clinical complete response" was defined as the absence of tumor cells on histopathologic evaluation. Of the patients with low-grade disease, 4 out of 5 exhibited a clinical complete response, with no tumor cells detected in histopathological evaluation post-treatment in the target and in several non-target bladder tumors. Two of 3 of the patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy, while tumor cells were still present on histopathological evaluation. Immune activation was noted in all patients in both treated target and untreated non-target bladder tumors with infiltration of effector CD8+ and CD4+ T-cells. This data provides evidence of a bladder urothelial field effect with a single low dose of bel-sar with light activation, potentially indicating a broader immune response in the bladder beyond the target tumor in these patients.

justiceforb_85 Posted - 1 month ago

$AURA $XBI awesome news for bladder cancer treatment. This, along with choroidal melanoma data, is fantastic. https://ir.aurabiosciences.com/news-releases/news-release-details/multiple-clinical-complete-responses-demonstrated-following

Harvo Posted - 1 month ago

$AURA tick tock

insiderbuyingselling Posted - 1 month ago

$AURA new insider selling: 7383 shares. http://insiderbuyingselling.com/?t=AURA

Doozio Posted - 1 month ago

🐑👀 LABD still had poppa huckleberry! bahhhht da FUTUre of 🧠⏰ is NOW n da $aura has spread n put it in LABD’s YANG during 🧠⏰♾️

valueforme Posted - 2 months ago

$CLSD 👇From last week's $AURA status updates call. Safety profile of suprachoroidal injections is underestimated

Stocksrunner Posted - 2 months ago

Analysts are bullish on $AURA $CSBR $FSLR $KIM are you ready for the potential gains? 📈 Check your portfolio and stay ahead of the curve! https://stocksrunner.com/posts/1135

Freddie___Mac Posted - 2 months ago

$AURA very promising data. Stock is very undervalued. Positive bladder data next month will expand the applicability of bel-sar

BioTuesdays Posted - 2 months ago

Aura Biosciences has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a life-threatening ocular cancer $AURA https://biotuesdays.com/2024/09/12/aura-announces-positive-phase-2-eos-results-evaluating-bel-sar-for-cm/